Germany / STADA’s Bold Bets on M&A
After a year of growth and acquisitions, 125-year-old German generics manufacturer STADA is showing a willingness to make bold bets on areas including consumer healthcare, medical cannabis, and research into…
Address: Am Karlsbad 15 / 10785 Berlin
Tel: +49 (0) 30 2639 2880
Cytolon is the first technology company to fulfill the central needs of personalized medicine. Personalized medicine is based on matching the patient´s personal genomic and histocompatibility data with the characteristics of a given product in order to achieve the best possible therapeutic effect. As medical treatments become more personalized, it will be increasingly important to be able to provide fast and accurate matching of patient data with therapeutic products for hundreds of thousands of patient cases at any time. A comprehensive solution can only be provided by intelligent internet-based matching platforms. As of today, there are no matching platforms that fulfill these needs. Cytolon was created to fill this gap.
Cytolon´s corporate mission is to be the world’s first trusted source for obtaining the correct, best-matched personalized product in a timely and cost-effective manner. Cytolon meets the requirements of personalized medicine through high performance matching, comprehensive logistics and secure data management for clinical development.
As allogeneic cord blood units and the stem cells contained within them are the first existing personalized products in clinical practice, Cytolon is initially focusing on this market. An accurate, timely matching process is imperative as a cord blood unit (CBU) must perfectly match the histocompatibility antigens and genetic needs of the patient and must be delivered within days.
Cytolon has developed a proprietary, patent-pending, global internet-based cord blood matching platform called CordMatch®. This platform is unique, as it integrates product search and matching, selection and logistics plus billing and follow-up.
After a year of growth and acquisitions, 125-year-old German generics manufacturer STADA is showing a willingness to make bold bets on areas including consumer healthcare, medical cannabis, and research into…
German biotech BioNTech has been thrust into the global spotlight thanks to its collaboration with global giant Pfizer on a COVID-19 vaccine. The company, founded by Professor Ugur Sahin in…
PharmaBoardroom recently sat down with Merck’s EVP and Head of Global Healthcare Operations, Teresa Rodó to unpack her important role within the global group and how Merck has pivoted to…
Merck KGaA has moved to continuously expand its manufacturing capacity and capability in recent years with a number of headline-grabbing investments in sites in its home market of Germany and…
Emmanuel Macron and Angela Merkel recently put their heads together to come up with a health strategy that would ensure greater European access to innovative medicines and COVID-19 treatments. …
Some of the top recent stories from Germany, Europe’s leading pharma market according to CPhI, including big new investments from Merck and Bayer, the implications of the country’s new Digital…
Bayer’s latest move to buy out BlueRock Therapeutics comes with a price tag of USD 600 million in total as the company increasingly looks toward cell and gene therapies to…
German giant Merck KGaA has announced a EUR one billion investment into its headquarters in Darmstadt, Germany up until 2025. The aim of Merck’s proposed investment is to secure…
As a majority family owned group, Merck is also the oldest pharmaceutical company in the world and known throughout the market for its long-term vision. How would you compare this…
The 2006 acquisition of Schering by Bayer is a prime example of the way that big pharma is now approaching growth through acquisition in this extremely competitive and challenging global…
DAIICHI SANKYO in Germany, Austria and Switzerland DAIICHI SANKYO wants to be a Global Pharma Innovator with Germany at the center of this process on the European continent. An example…
Many companies that are focused in the diabetes segment have recognised the need to strengthen their operations in emerging markets, due to the increased prevalence of the disease in countries…
See our Cookie Privacy Policy Here
